Back to Search
DAVID CHRIST, M.D.
M.D.
Specialist
NPI: 1922072297IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
24150(IA)
Education
KANSAS MEDICAL COLLEGE
Class of 1979
Research & Publications (20)
Sequence determinants of protein aggregation in human VH domains.
PMID 18957405·Protein Eng Des Sel·2009
8-other
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
PMID 18788723·J Med Chem·2008
7-preclinical
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
PMID 18032037·Bioorg Med Chem Lett·2008
7-preclinical
Thermodynamically stable aggregation-resistant antibody domains through directed evolution.
PMID 18199455·J Mol Biol·2008
8-other
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.
PMID 17914718·J Pharm Sci·2008
7-preclinical
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
PMID 18061445·Bioorg Med Chem Lett·2008
7-preclinical
Engineering Escherichia coli heat-resistance by synthetic gene amplification.
PMID 18175777·Protein Eng Des Sel·2008
8-other
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
PMID 18234496·Bioorg Med Chem Lett·2008
7-preclinical
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.
PMID 18242982·Bioorg Med Chem Lett·2008
7-preclinical
Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
PMID 18282708·Bioorg Med Chem Lett·2008
7-preclinical
Repertoires of aggregation-resistant human antibody domains.
PMID 17720749·Protein Eng Des Sel·2007
4-observational
Species-specific, P450- and sulfotransferase-mediated novel ring contraction of a naphthyridine-N-oxide compound in cynomolgus monkey.
PMID 17939741·Chem Res Toxicol·2007
7-preclinical
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.
PMID 17276676·Bioorg Med Chem Lett·2007
7-preclinical
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
PMID 17656469·Drug Metab Dispos·2007
3-trial
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.
PMID 17418570·Bioorg Med Chem Lett·2007
7-preclinical
Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine.
PMID 17162465·Xenobiotica·2006
4-observational
Tapping diversity lost in transformations--in vitro amplification of ligation reactions.
PMID 16945952·Nucleic Acids Res·2006
8-other
Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
PMID 15163180·J Med Chem·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1200 1ST AVE E, SUITE B
SPENCER, IA 51301 - Phone
- (712) 262-6214
Quick Facts
- NPI
- 1922072297
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 47
- Publications
- 20
Are you this provider?
Claim Your Profile